DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid neuropeptide first isolated from the cerebral venous blood of sleeping rabbits in 1974 by Monnier and Schoenenberger. Its name reflects the initial observation that infusion induced delta-wave sleep (slow-wave EEG activity) in research animals. Subsequent research has documented broader neuromodulatory activity including effects on stress-axis regulation, opioid receptor pathways and thermoregulation. The compound remains the subject of ongoing sleep-architecture research and is sometimes studied as a component in sleep-focused stack formulations alongside epithalon.
DSIP's mechanism is incompletely characterised relative to other research peptides. Multiple putative mechanisms have been documented in published research, with no single dominant receptor or pathway identified. The original observation — delta-wave EEG induction following intraventricular infusion in rabbits — has been replicated across multiple species and protocols, establishing the behavioural effect even where the receptor-level mechanism remains debated.
Documented activity includes modulation of opioid receptor pathways (DSIP antagonises some morphine-induced behaviours in rodent models), HPA-axis regulation (attenuating corticosterone responses to stress in published preclinical work), and possible direct effects on brainstem sleep-regulatory nuclei. Several proteomic studies have identified DSIP-binding proteins but no canonical G-protein coupled receptor.
The very short plasma half-life (~7-15 minutes) suggests rapid degradation by aminopeptidases, with biological effects possibly mediated through cleavage products or transient receptor occupancy. This pharmacokinetic profile is the principal challenge in translational DSIP research.
DSIP research originated in the 1970s with Monnier and Schoenenberger's isolation from cerebral venous blood of sleeping rabbits. The peptide was named for its observed induction of delta-wave (slow-wave) EEG activity following intraventricular infusion. Subsequent rodent and feline research consistently replicated the EEG observation.
Translation to non-CNS routes has been more challenging due to the short plasma half-life. Some clinical work in the 1980s explored DSIP for chronic insomnia with mixed results; the field is currently quiet in commercial development but the peptide remains a research probe for slow-wave-sleep biology and is included in some sleep-focused stack research alongside epithalon (which acts on chronic pineal-axis circadian regulation rather than acute sleep induction).
Beyond sleep, DSIP has been studied for HPA-axis attenuation following stress challenges in published preclinical research. Reductions in cortisol/corticosterone responses to acute stressors have been documented, though the underlying mechanism remains unclear.
Opioid-pathway interactions have been documented since the 1980s — DSIP modulates some morphine-induced behaviours in rodents, suggesting indirect engagement of endogenous opioid signalling. This research line remains active but has not progressed to translational development.